Hydroxylamine derivatives have interesting chemical properties. They can be readily reduced to amines and readily oxidized to nitrones. Additionally, the oxidation of hydroxylamine by ceric sulfate 2) and OH-radicals 3) produces NH 2 O · radicals. Therefore, if such a substituent can be introduced into the sugar moiety of a nucleoside, the result may be a unique nucleoside with a variety of biological activities. Recently, we synthesized several nucleosides with a hydroxyamino group instead of a hydroxyl group of the 2Ј or 3Ј position at the sugar moiety. Among them, 2Ј-deoxy-2Ј-hydroxyaminocytidine (2Ј-DHAC) and 3Ј-deoxy-3Ј-hydroxyaminocytidine (3Ј-DHAC) ( Fig. 1) showed cytotoxicity against several tumor cell lines in vitro, and antileukemic activity against the mouse P388 model in vivo. 4, 5) We also detected 2Ј-NHO · radicals of 2Ј-DHAC in neutral aqueous solution at room temperature by ESR. 4) A nucleoside with a hydroxyamino group instead of a hydroxymethyl group at the 4Ј-position of the sugar moiety, such as 1, (Fig. 1) would be expected to be a substrate of certain nucleoside kinases, since the hydroxyamino group may mimic to the hydroxymethyl group. However, substitution of the hydroxymethyl group of a D-ribose or 2-deoxy-D-ribose moiety by a hydroxyamino group would be difficult because that such nucleosides are not sufficiently stable. Therefore, we designed and synthesized carbocyclic nucleoside analogues with a hydroxyamino group at the carbocyclic moiety, such as 2-4 depicted in Fig. 1 , and evaluated their cytotoxicity against tumor cells in vitro and their antiviral activities against human immunodeficiency virus type-1 (HIV-1) in vitro.
Chemistry
The synthetic route to the target compounds is outlined in Chart 1. The target compounds were straightforwardly synthesized using Pd-chemistry. Enantiomerically pure (ϩ)-(1R,4S)-1-acetoxy-4-hydroxy-2-cyclopentene (6) was obtained by hydrolysis of the corresponding racemic diacetate 5 with porcine liver esterase in 99% ee. 6) Compound 5 was protected with a tert-butyldiphenylsilyl (TBDPS) group, followed by deacetylation to give 8, which was converted into an ethoxycarbonyl derivative 9. Compound 9 was reacted with N3-benzoylthymine 7) in the presence of Pd 2 (dba) 3 · CHCl 3 and Ph 3 P to smoothly give the desired thymine-carbocycle 10 in 94% yield. The configuration at the 1Ј-position was confirmed by nuclear Overhauser effect (NOE) experiments. When the 5Јa-proton in 10 was irradiated, NOE enhancements of 18% and 16% were observed at the 1Ј and 4Ј-protons, respectively. Therefore, N3-benzoylthymine was introduced via a double inversion, and 10 has the desired configuration at the 1Ј-position. To introduce nucleobases into similar carbocycles using Pd-chemistry, previous methods have used an acetoxy or benzoyloxy group as a leaving group. 8, 9) In our experiments, the ethoxycarbonyloxy group was found to be a good choice as the leaving group, as expected. Deprotection of the TBDPS group by tetrabutylammonium fluoride (TBAF), followed by ethoxycarbonylation of the resulting hydroxyl group, gave a substrate 14 for the next Pd-catalyzed reaction to introduce a hydroxylamino group at the 4Ј-position. Compound 14 was treated with O-benzylhydroxylamine under conditions similar to those described above to give 16 in 84% yield. Removal of the benzoyl group at the N3-position using NaOMe and subsequently the Obenzyl group by BCl 3 gave 20 in 80% yield in two steps.
Compound 20 provides a 4Ј-hydroxyaminated-carbocyclic equivalent of the anti-HIV agent 2Ј,3Ј-didehydro-2Ј,3Ј-dideoxythymidine (D4T). After protection of the hydroxyl group in 20 with a TBDPS group, the resulting 22 was hydrogenated in the presence of Pd/C in AcOEt to give cyclopentyl derivative 24 in 89% yield. When the same reaction was performed in MeOH, the N-O bond cleavage was also detected along with 24. The TBDPS group in 24 was removed by treatment with HCl in a mixture of dioxane and MeOH to give 26 as a hydrochloride.
Uracil derivatives 21 and 27 were synthesized in a manner similar to that described for the synthesis of thymine analogues, as shown in Chart 1.
Compound 23 was cis-dihydroxylated using OsO 4 in the presence of 4-methylmorpholine N-oxide (NMO) to give 28 in 67% yield. The stereochemistry of 28 was determined using NOE experiments. Upon irradiation of the 1Ј-proton of 28, 1.2% enhancement was observed at the 4Ј-proton, and 1.9% enhancement at the 2Ј-proton was detected upon irradiation of the 6-proton at the uracil moiety. Therefore, cis-dihydroxylation selectively occurred at the a-face of the carbocyclic ring. Deprotection of the TBDPS group in 28 with TBAF gave carbocyclic uridine derivative 29.
Protection of the cis-hydroxyl group in 28 with a tertbutyldimethylsilyl (TBS) group gave 30, which was further converted into a cytosine derivative 31 in a usual manner. Finally, 31 was deprotected with HCl in a mixture of dioxane and MeOH to give carbocyclic cytidine analogue 32 as a dihydrochloride.
Biological Activity
The cytotoxicities of 4Ј-hydroxyamino-substituted carbocyclic nucleosides 20, 21, 26, 27, 29 and 32 were investigated in vitro using mouse L1210 leukemia and human KB pharyngeal carcinoma cells. 10) The results are summarized in Table 1 . Among the nucleosides, D4T analogue 20 was the most effective, with IC 50 values of 27.3 and 34.5 mM against KB and L1210 cells in vitro, while uracil analogue 21 was only effective against L1210 cells, with an IC 50 value of 88 mM. Cyclopentyl analogues 26 and 27 were devoid of any activities against both cell lines. Carbocyclic ribo-nucleoside analogues 29 and 32 were less cytotoxic than 20, and cytosine analogue 32 was slightly more active than uracil analogue 29.
The antiviral activities of the nucleosides against HIV-1 Chart 1
were also examined in vitro (Table 1) . 11) However, 20, 21, and 26 were too cytotoxic to the host human T-leukemic MT-4 cells to measure their anti-HIV activities. Compound 27 showed no activity against HIV at up to 300 mM.
Although we do not have any direct evidence that these carbocyclic nucleosides became substrates of certain nucleoside kinases, based on the biological data shown in Table 1 , there appears to be some nucleobase specificity for the cytotoxicity; thymine derivative 20 is more active than uracil derivative 21, and cytosine derivative 32 is more active than uracil derivative 29. These results could reflect the substrate specificities of thymidine kinase and uridine/cytidine kinase. Moreover, 20, 21, and 26 were more active against human leukemic MT-4 cells than against human KB cells, which are derived from solid tumors. These results could reflect that kinase activity is usually higher in T-leukemic cells than in cells derived from solid tumors. Therefore, it is likely that the hydroxyamino group may be a bioisostere of the hydroxymethyl group in nucleosides, and accepts a phosphate group by certain nucleoside kinases.
Experimental
Melting points were measured on a Yanagimoto MP-3 micromelting point apparatus (Yanagimoto, Japan) and are uncorrected. Fast atom bombardment mass spectrometry (FAB-MS) was done on a JEOL JMS-HX110 instrument at an ionizing voltage of 70 eV. The 1 H-NMR spectra were recorded on a JEOL JNM-GX 270 (270 MHz) or Bruker ARX 500 (500 MHz) spectrometer with tetramethylsilane as an internal standard. Chemical shifts are reported in parts per million (d), and signals are expressed as s (singlet), d (doublet), t (triplet), m (multiplet), or br (broad). All exchangeable protons were detected by disappearance on the addition of D 2 O. UV absorption spectra were recorded with a Shimadzu UV-240 spectrophotometer. IR spectra were recorded with a JEOL A-102 spectrometer. TLC was done on Merck Kieselgel F 254 precoated plates (Merck, Germany). The silica gel used for column chromatography was YMC gel 60A (70-230 mesh) (YMC Co., Ltd., Japan).
(؉)-(1R,4S)-1-Acetoxy-4-hydroxy-2-cyclopentene (6) Porcine liver esterase (45 g, purchased from Sigma) was added to a stirred solution of 5 (43.0 g, 233 mmol) in phosphate buffer (0.1 M, 200 ml, pH 7.0) at 37°C. The mixture was stirred at 37°C for 2 days and quenched by addition of EtOH (200 ml). The mixture was filtered through a Celite pad, which was washed with AcOEt. The combined filtrate and washings were concentrated in vacuo, and the residue was extracted with CHCl 3 (500 mlϫ5). The organic layer was dried (Na 2 SO 4 ) and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane : AcOEtϭ2 : 1) to give 6 (11.2 g, 34% as a yellow oil): [a] (
1R,4S )-4-[(tert-Butyldiphenylsilyl)oxy]-1-(ethoxycarbonyloxy)-2-cyclopentene (9)
A mixture of 6 (5.60 g, 39.4 mmol), TBDPSCl (15.2 ml, 58.5 mmol), and imidazole (5.31 g, 78.0 mmol) in dimethylformamide (DMF, 100 ml) was stirred 24 h at 0°C and diluted with Et 2 O (500 ml). The mixture was washed with H 2 O (200 mlϫ2) and brine (200 ml), dried (Na 2 SO 4 ), and concentrated in vacuo to give crude 7 as a colorless oil. A MeOH solution of NaOMe (28%, 1.27 ml) was added to the above oil in MeOH (100 ml), and the mixture was stirred for 24 h at room temperature. The mixture was neutralized with Dowex-50W X2 (H ϩ -form) and filtered. The filtrate was concentrated in vacuo to give crude 8 as a colorless oil, which was coevaporated several times with pyridine. ClCO 2 Et (11.2 ml, 117 mmol) was added to a solution of the above oil in pyridine (150 ml) at 0°C under argon atmosphere. After the mixture was stirred for 1.5 h at room temperature, the reaction was quenched by addition of H 2 O at 0°C, and the solvent was removed in vacuo. The residue was dissolved in Et 2 O (250 ml), which was washed with H 2 O (250 mlϫ2) and brine (250 ml), dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane : AcOEtϭ10 : 1) to give 9 (15.6 g, 97% as a colorless oil 
N3-Benzoyl-1-[(1R,4S )-4-[(tert-butyldiphenylsilyl)oxy]-2-cyclopenten-1-yl]uracil (11)
A mixture of 6 (6.77 g, 16.5 mmol), N 3-benzoyluracil (4.60 g, 21.3 mmol), Pd 2 (dba) 3 · CHCl 3 (735 mg, 0.71 mmol), and PPh 3 (1.46 g, 5.68 mmol) in THF (100 ml) was stirred for 3 h at room temperature under argon atmosphere. Work-up and purification were performed as described above to give 11 (8.45 
N3-Benzoyl-1-[(1R,4S)-4-hydroxy-2-cyclopenten-1-yl]thymine (12)
A mixture of 10 (5.30 g, 9.62 mmol) and TBAF (1 M in THF, 11.6 ml, 11.6 mmol) in THF (50 ml) was stirred at room temperature for 30 min, and the solvent was removed in vacuo. The residue was coevaporated several times with MeOH and purified by silica gel column chromatography (CHCl 3 : EtOHϭ15 : 1) to give 12 (3.00 g, quant. as a white foam). 10) Each tumor cell (2ϫ10 3 cells/well) was incubated in the presence or absence of compounds for 72 h. 3(4,5-dimethylthizol-2-yl)-2,5-dimethyltetrazolium bromide (MTT)-reagent was added to each well and plate was incubated for 4 h more, the resulting MTT-formazan was dissolved in DMSO and the OD (540 nm) was measured. Percent inhibition was calculated as follows: % inhibitionϭ[1ϪOD (540 nm) of sample well/OD (540 nm) of control well]ϫ100. IC 50 (mg/ml) was given as the concentration at 50% inhibition of cell growth. b) To evaluate anti-HIV-1 activity, HIV-1 IIIb strain vs. MT-4 cells were used, respectively. Briefly, cells were infected with viruses at a multiplicity of infection (m.o.i.) of 0.02. Immediately after the virus infection, a cell suspension (100 ml) was placed into each well containing various concentrations of the compounds (100 ml). After 4 days of incubation at 36°C, the number of viable cells was determined by the MTT method.
11)
c) Not determined.
in THF (30 ml) was stirred at room temperature for 4 h. Work-up and purification were performed as described above to give 13 (1.09 g, 91% as a pale yellow foam 
1767). N 3-Benzoyl-1-[(1R,4S )-4-(N-benzyloxyamino)-2-cyclopenten-1-yl]-uracil (17)
A mixture of 15 (1.10 g, 2.97 mmol), Pd 2 (dba) 3 · CHCl 3 (154 mg, 0.149 mmol), and PPh 3 (311 mg, 1.19 mmol) was added to a stirred solution of aqueous NaOH (2 M, 2.33 ml, 4.46 mmol) and NH 2 OBn · HCl (711 mg, 4.46 mmol) in THF (20 ml) at room temperature. After the mixture was stirred for 7 h at room temperature, work-up and purification were performed as described above to give 17 (1.0 g, 84% as a pale yellow foam). 1 
1-[(1R,4S)-4-(N-Benzyloxyamino)-2-cyclopenten-1-yl]thymine (18)
A mixture of 16 (1.67 g, 4.00 mmol) in MeOH (30 ml) containing NaOMe (28%, 1 ml) was stirred for 24 h at room temperature, and neutralized by addition of aqueous HCl (1 M), and the solvent was removed in vacuo. The residue was purified by silica gel column chromatography (CHCl 3 : AcOEtϭ 1-[(1R,4S)-4-(N-Hydroxyamino)-2-cyclopenten-1-yl]thymine (20) A  mixture of 18 (1.2 g, 3.8 mmol) and BCl 3 (1 M in CH 2 Cl 2 , 20 ml) was stirred for 2 days at room temperature, and the reaction was quenched by addition of MeOH, and the solvent was removed in vacuo. The residue was coevaporated several times with MeOH, and purified by silica gel column chromatography (CHCl 3 : MeOHϭ10 : 1) to give 20 (777 mg, 91% as a white foam). 
1-[(1R,4S )-4-(N-Benzyloxyamino)-2-cyclopenten-1-yl]uracil (19)
A mixture of 17 (1.60 g, 3.97 mmol) in MeOH (30 ml) containing NaOMe (28%, 1 ml) was stirred for 24 h at room temperature, and neutralized by addition of aqueous HCl (1 M 
1-[(1R,4S )-4-(N-Hydroxyamino)-2-cyclopenten-1-yl]uracil (21)
A mixture of 19 (50 mg, 0.17 mmol) and BCl 3 (1 M in CH 2 Cl 2 , 2 ml) in CH 2 Cl 2 (1 ml) was stirred for 24 h at room temperature at room temperature, workup and purification were performed as described above to give 21 (30 mg, 86% as a white solid), mp 176-178°C. 
1-[(1R,4S )-4-[N-(tert-Butyldiphenylsilyl)oxyamino]-2-cyclopenten-1-yl]thymine (22)
A mixture of 20 (488 mg, 2.19 mmol), TBDPSCl (779 ml, 3.00 mmol), and imidazole (272 mg, 4.01 mmol) in DMF (10 ml) was stirred for 2 days at room temperature and diluted with AcOEt (15 ml), which was washed with H 2 O (10 mlϫ3) and brine (10 ml), dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane : AcOEtϭ1 : 1) to give 22 (523 mg, 52% as a white foam). 
1-[(1R,4S )-4-[N-(tert-Butyldiphenylsilyl)oxyamino]-2-cyclopenten-1-yl]uracil (23)
A mixture of 21 (37 mg, 0.18 mmol), TBDPSCl (69 ml, 0.27 mmol) and imidazole (24 mg, 0.35 mmol) in DMF (1 ml) was stirred for 24 h at room temperature for 24 h. Work-up and purification were performed as described above to give 23 (70 mg, 88% as a white foam). 1-[(1S,4R)-4-[N-(tert-Butyldiphenylsilyl)oxyamino]cyclopent-1-yl] thymine (24) A mixture of 22 (138 mg, 0.299 mmol) and 10% Pd-C (20 mg) in AcOEt (3 ml) was stirred for 24 h under H 2 atmosphere at room temperature and filtered through a Celite pad, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane : AcOEtϭ1 : 1) to give 24 (117 mg, 84% as a white foam (1H, m, H-4Ј), 2.24 (1H, ddd, H-5Јa, Jϭ7.3, 9.6, 14.1 Hz), 1.80 (2H, m,  H-3Ј), 1.72 (3H, s, 5-Me), 1.55 (1H, m, H-5Јb), 1.21 (2H, m, H-2Ј 
1-[(1R,2S,3R,4S )-4-[N-(tert-Butyldiphenylsilyl)oxyamino]-2,3-dihydroxycyclopent-1-yl]uracil (28)
A mixture of 23 (400 mg, 0.89 mmol), NMO (210 mg, 1.79 mmol) and OsO 4 (5 mg/ml in tert-BuOH containing 1% tert-BuOOH, 6 ml, 0.12 mmol) in THF (2 ml) and H 2 O (2 ml) was stirred for 2 h at room temperature and further amounts of NMO (100 mg, 0.852 mmol) and OsO 4 (3 ml, 0.06 mmol) were added to the mixture at 0°C. After the mixture was stirred for further 2 h at room temperature, the reaction was quenched by addition of saturated aqueous Na 2 S 2 O 3 , and the mixture was extracted with AcOEt (50 ml). The organic layer was washed with H 2 O (30 ml), saturated aqueous NaHCO 3 (20 ml), saturated aqueous Na 2 S 2 O 3 (30 ml), and brine (30 ml), dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by silica gel column chromatography (CHCl 3 : MeOHϭ20 : 1) to give 28 (288 mg, 67% as a white foam 1-[(1R,2S,3R,4S )-2,3-Dihydroxy-4-(N-hydroxyamino) , and imidazole (68 mg, 1.0 mmol) in DMF (2 ml) was stirred for 2 h at room temperature, and further amounts of TBSCl (60 mg, 0.40 mmol) and imidazole (54 mg, 0.80 mmol) were added to the mixture at 0°C. After the mixture was stirred for 24 h at room temperature, the mixture was diluted with AcOEt (15 ml), which was washed with H 2 O (15 mlϫ3) and brine, dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane : AcOEtϭ3 : 1) to give 30 (128 mg, 90% as a white foam). .064 mmol) in CH 3 CN (1 ml) was stirred for 1.5 h at room temperature, then NH 4 OH (28%, 1 ml) was added to the mixture at room temperature. After 3 h, the resulting mixture was diluted with AcOEt (25 ml), which was washed with H 2 O (25 ml) and brine (25 ml), dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by silica gel column chromatography (CHCl 3 : MeOHϭ50 : 1) to give 31 (62 mg, 56% as a pale yellow foam). 1,4 -dioxane, 0.5 ml) was stirred for 5 h at room temperature, and the solvent was removed in vacuo. The residue was coevaporated several times with EtOH, which was dissolved in H 2 O (15 ml), and the aqueous layer was washed with CHCl 3 (15 mlϫ3) and concentrated in vacuo. The residue was coevaporated several times with EtOH and Et 2 O, and the resulting crystals were collected by filtration to give 32 (23 mg, quant. as a white crystalline), mp 145-148°C. 1 
